U

University of Kentucky | Kentucky Clinic, Kentucky Neuroscience Institute

Research site
(Unclaimed)
Location
740 S Limestone Street, Lexington, Kentucky, United States of America
Site insights

Top conditions

Alzheimer Disease (31 trials)

Cystic Fibrosis (24 trials)

Fibrosis (22 trials)

Leukemia (22 trials)

Lung Cancer (17 trials)

Top treatments

Cyclophosphamide
Alcohol
Gemcitabine
Etoposide
Methotrexate
Cisplatin
Paclitaxel
Carboplatin
Vincristine
Irinotecan

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

82 of 668
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lympho...

Active, not recruiting
Leukemia
Drug: Cytarabine
Drug: Leucovorin Calcium

A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disea...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: AL002

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in pa...

Active, not recruiting
Cystic Fibrosis
Drug: VX-121/TEZ/D-IVA

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting
FIGO Stage III-IV
Newly Diagnosed
Drug: Rucaparib
Drug: Placebo Oral Tablet

This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in thi...

Enrolling
Extensive Stage Small Cell Lung Cancer
Drug: [177Lu]Lu-DOTA-TATE
Drug: Atezolizumab

This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FP...

Enrolling
NTSR1 Expressing Solid Tumours
Gastric Cancer
Drug: [225]-FPI-2059
Drug: [111In]-FPI-2058

This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line th...

Active, not recruiting
Glioblastoma Multiforme, Adult
Drug: Berubicin
Drug: Lomustine

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administratio...

Enrolling
Multiple Myeloma
Drug: Cyclophosphamide
Drug: Cilta-cel

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Enrolling
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab
Locations recently updated

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies

Enrolling
Advanced Solid Tumor
Drug: EP0031

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic...

Active, not recruiting
Isocitrate Dehydrogenase Gene Mutation
Drug: HMPL-306

The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims...

Enrolling
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Drug: JNJ-90009530

A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor ac...

Active, not recruiting
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Drug: Linagliptin
Drug: Cobimetinib

The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected TKI for the treatment of newly diagnosed, previously...

Active, not recruiting
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Drug: Dasatinib
Drug: Imatinib

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Enrolling
Melanoma
Solid Tumor, Adult
Drug: KIN-2787
Drug: KIN-2787 and binimetinib

This is a Phase 1/2 multi-center, open label, dose escalation and dose expansion study to evaluate safety, tolerability, dosimetry, pharmacodynamics...

Active, not recruiting
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
Drug: CAM-H2
Locations recently updated

A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.

Enrolling
Fuchs Endothelial Corneal Dystrophy
Drug: Placebo
Drug: Ripasudil

This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Enrolling
SARS-CoV-2
Biological: mRNA-1273.214
Biological: mRNA-1273.815
Locations recently updated

A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.

Enrolling
Fuchs Endothelial Corneal Dystrophy
Drug: Placebo
Drug: Ripasudil

Trial sponsors

University of Kentucky logo

University of Kentucky (30 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems